IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PRAXAIR DISTRIBUTION, INC. Petitioner v. INO THERAPEUTICS, INC. d/b/a IKARIA, INC. Patent Owner

### PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 8,282,966 <u>PURSUANT TO §§ 35 U.S.C. 311-319 AND 37 C.F.R. § 42</u>

#### **Mail Stop PATENT BOARD**

Patent Trial and Appeal Board United States Patent and Trademark Office PO Box 1450 Alexandria, Virginia 22313–1450

# **Table of Contents**

I.	INTRODUCTION					
II.	OVERVIEW					
	A.	Summary of the '966 Patent1				
	B. S	Summary of the Prosecution History of the '966 Patent				
III.	RESPI	CKGROUND ON PULMONARY HYPERTENSION, HYPOXIC SPIRATORY FAILURE, AND DIAGNOSTIC STEPS USED IN EATMENT				
IV.	GROU	ROUNDS FOR STANDING (37 C.F.R. § 42.104(a))				
V.	PAYM	PAYMENT OF FEES (37 C.F.R. § 42.103)				
VI.	MANDATORY NOTICES (37 C.F.R. § 42.8)					
	A. I	Real-Parties-in-Interest7				
	B. I	Related Matters7				
		Lead and Backup Counsel (37 C.F.R. § 42.8(b)(3)) and Service Information (37 C.F.R. § 42.8(b)(4))7				
VII.	PERSO	PERSON OF ORDINARY SKILL IN THE ART				
VIII.	CLAIM CONSTRUCTION					
	A. Broadest Reasonable Interpretation Standard					
	B. (	Claim Construction of the Term "Child" and "Children"10				
IX.	. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFORE (37 C.F.R. §§ 42.22(a) and 42.104(b))					
	(	Ground 1: Independent Claims 1, 6, 13, and 22 and Dependent Claims 2-3, 5, 7-9, 11, 14-17, 20, 23-25, and 28 are Unpatentable Under 35 U.S.C. § 103(a) as Obvious Over <i>Bernasconi</i> in View of <i>INOMAX label, Loh</i> and <i>Goyal</i>				
		1. Overview of Prior Art Applied in Ground 1				
	4	2. Motivation to Combine Art Applied in Ground 1				
		3.Independent Claims 1 and 621				
		(a) Part (a) of Independent Claims 1 and 622				
		(b) Part (b) of Independent Claims 1 and 625				

		(c)	Part (c) of Independent Claims 1 and 6	27		
	4.	Indep	bendent Claims 13 and 22	28		
		(a)	Part (a) of Independent Claims 13 and 22	28		
		(b)	Part (b) of Independent Claims 13 and 22	29		
		(c)	Part (c) of Independent Claims 13 and 22	30		
		(d)	Part (d) of Independent Claims 13 and 22	31		
		(e)	Part (e) of Independent Claims 13 and 22	31		
	5.	Depe	ndent Claims 2-3, 5, 7-9, 11, 14-17, 20, 23-25, and 28	32		
		(a)	Dependent Claims 2 and 8	32		
		(b)	Dependent Claims 3, 9, and 16	33		
		(c)	Dependent Claims 5, 11, 20, and 28	33		
		(d)	Dependent Claims 14 and 24	34		
		(e)	Dependent Claims 15 and 25	35		
		(f)	Dependent Claims 7, 17, and 23	35		
B.		nd 2: Dependent Claims 4, 10, 12, 18, 19, 21, 26, 27, and 29 npatentable Under 35 U.S.C. § 103(a) as Obvious Over <i>sconi</i> , the <i>INOMAX label</i> , <i>Loh</i> , <i>Goyal</i> and <i>Macrae</i>				
	Berna	-	ů ()			
C.	Groun Claim U.S.C	nd 3: I nd 3: I ns 2-5, 2. § 10	, the <i>INOMAX label</i> , <i>Loh</i> , <i>Goyal</i> and <i>Macrae</i> ndependent Claims 1, 6, 13, and 22 and Dependent 7-12, 14-21, and 23-29 are Unpatentable Under 35 3(a) as Obvious Over <i>Ichinose</i> , <i>Neonatal Group</i> ,			
C.	Groun Claim U.S.C <i>Macro</i>	nd 3: I nd 3: I ns 2-5, 2. § 10 ae, Lo	, the <i>INOMAX label</i> , <i>Loh</i> , <i>Goyal</i> and <i>Macrae</i> ndependent Claims 1, 6, 13, and 22 and Dependent 7-12, 14-21, and 23-29 are Unpatentable Under 35 3(a) as Obvious Over <i>Ichinose</i> , <i>Neonatal Group</i> , <i>h</i> , <i>Goyal</i> , and <i>Germann</i>	39		
C.	Groun Claim U.S.C <i>Macro</i> 1.	nd 3: I ns 2-5, 2. § 10 ae, Lo. Overy	, the <i>INOMAX label</i> , <i>Loh</i> , <i>Goyal</i> and <i>Macrae</i> ndependent Claims 1, 6, 13, and 22 and Dependent 7-12, 14-21, and 23-29 are Unpatentable Under 35 3(a) as Obvious Over <i>Ichinose</i> , <i>Neonatal Group</i> , <i>h</i> , <i>Goyal</i> , and <i>Germann</i> view of Prior Art in Ground 3	39 40		
C.	Groun Claim U.S.C <i>Macro</i> 1. 2.	usconi, nd 3: I ns 2-5, C. § 10 ae, Lo Overv Motiv	, the <i>INOMAX label</i> , <i>Loh</i> , <i>Goyal</i> and <i>Macrae</i> ndependent Claims 1, 6, 13, and 22 and Dependent 7-12, 14-21, and 23-29 are Unpatentable Under 35 3(a) as Obvious Over <i>Ichinose</i> , <i>Neonatal Group</i> , <i>h</i> , <i>Goyal</i> , and <i>Germann</i> view of Prior Art in Ground 3	39 40 41		
C.	Groun Claim U.S.C <i>Macro</i> 1.	usconi, nd 3: I ns 2-5, C. § 10 ae, Lo Overv Motiv	, the <i>INOMAX label</i> , <i>Loh</i> , <i>Goyal</i> and <i>Macrae</i> ndependent Claims 1, 6, 13, and 22 and Dependent 7-12, 14-21, and 23-29 are Unpatentable Under 35 3(a) as Obvious Over <i>Ichinose</i> , <i>Neonatal Group</i> , <i>h</i> , <i>Goyal</i> , and <i>Germann</i> view of Prior Art in Ground 3	39 40 41 43		
C.	Groun Claim U.S.C <i>Macro</i> 1. 2.	usconi, nd 3: I ns 2-5, 2. § 10 <i>ae</i> , <i>Lo</i> Over Motiv Indep	, the <i>INOMAX label</i> , <i>Loh</i> , <i>Goyal</i> and <i>Macrae</i> ndependent Claims 1, 6, 13, and 22 and Dependent 7-12, 14-21, and 23-29 are Unpatentable Under 35 3(a) as Obvious Over <i>Ichinose</i> , <i>Neonatal Group</i> , <i>h</i> , <i>Goyal</i> , and <i>Germann</i> view of Prior Art in Ground 3 vation to Combine Art Applied in Ground 3	39 40 41 43 43		
C.	Groun Claim U.S.C <i>Macro</i> 1. 2.	usconi, nd 3: I ns 2-5, 2. § 10 <i>ae</i> , <i>Lo</i> Overy Motiv Indep (a)	, the <i>INOMAX label</i> , <i>Loh</i> , <i>Goyal</i> and <i>Macrae</i> ndependent Claims 1, 6, 13, and 22 and Dependent 7-12, 14-21, and 23-29 are Unpatentable Under 35 3(a) as Obvious Over <i>Ichinose</i> , <i>Neonatal Group</i> , <i>h</i> , <i>Goyal</i> , and <i>Germann</i> view of Prior Art in Ground 3 vation to Combine Art Applied in Ground 3 pendent Claims 1 and 6 Part (a) of Independent Claims 1 and 6	39 40 41 43 43 43		
C.	Groun Claim U.S.C <i>Macro</i> 1. 2.	usconi, nd 3: I ns 2-5, 2. § 10 ae, Lo. Overv Motiv Indep (a) (b) (c)	, the <i>INOMAX label</i> , <i>Loh</i> , <i>Goyal</i> and <i>Macrae</i> ndependent Claims 1, 6, 13, and 22 and Dependent 7-12, 14-21, and 23-29 are Unpatentable Under 35 3(a) as Obvious Over <i>Ichinose</i> , <i>Neonatal Group</i> , <i>h</i> , <i>Goyal</i> , and <i>Germann</i> view of Prior Art in Ground 3 vation to Combine Art Applied in Ground 3 pendent Claims 1 and 6 Part (a) of Independent Claims 1 and 6 Part (b) of Independent Claims 1 and 6	39 40 41 43 43 43 47 48		
C.	Groun Claim U.S.C <i>Macro</i> 1. 2. 3.	usconi, nd 3: I ns 2-5, 2. § 10 ae, Lo. Overv Motiv Indep (a) (b) (c)	, the <i>INOMAX label</i> , <i>Loh</i> , <i>Goyal</i> and <i>Macrae</i> ndependent Claims 1, 6, 13, and 22 and Dependent 7-12, 14-21, and 23-29 are Unpatentable Under 35 3(a) as Obvious Over <i>Ichinose</i> , <i>Neonatal Group</i> , <i>h</i> , <i>Goyal</i> , and <i>Germann</i> view of Prior Art in Ground 3 vation to Combine Art Applied in Ground 3 pendent Claims 1 and 6 Part (a) of Independent Claims 1 and 6 Part (b) of Independent Claims 1 and 6	39 40 41 43 43 43 47 48 49		

(c)	Part (c) of Independent Claims 13 and 22	51
(d)	Part (d) of Independent Claims 13 and 22	52
(e)	Part (e) of Independent Claims 13 and 22	53
5. Dep	pendent Claims 2-5, 7-12, 14-21, and 23-29	54
(a)	Dependent Claims 2 and 8	54
(b)	Dependent Claims 3, 9, and 16	54
(c)	Dependent Claims 5, 11, 20, and 28	55
(d)	Dependent Claims 14 and 24	56
(e)	Dependent Claims 15 and 25	56
(f)	Dependent Claims 7, 17, and 23	57
(g)	Dependent Claims 4, 10, 12, 18, 19, 21, 26, 27, 29.	58
CONCLUSION		58

Х.

#### **List of Exhibits**

- Ex. 1001: U.S. Patent No. 8,282,966 to Baldassarre *et al.* ("'966 Patent), filed June 22, 2010, issued October 9, 2012.
- Ex. 1002: Declaration of Dr. Maurice Beghetti.
- Ex. 1003: *Curriculum vitae* of Dr. Maurice Beghetti.
- Ex. 1004: Bernasconi et al., Inhaled Nitric Oxide Applications in Paediatric Practice, 4 Images in Paediatric Cardiology, 4-29 (2002). ("Bernasconi").
- Ex. 1005: Davidson, et al., Inhaled Nitric Oxide for the Early Treatment of Persistent Pulmonary Hypertension of the Term Newborn: A Randomized, Double-Masked, Placebo-Controlled, Dose-Response, Multicenter Study, 101 Pediatrics, 325-334 (1998). ("Davidson").
- Ex. 1006: Loh, et al., Cardiovascular Effects of Inhaled Nitric Oxide in Patients with Left Ventricular Dysfunction, 90 Circulation, 2780-2785 (1994).
  ("Loh").
- Ex. 1007: P. Goyal, et al., Efficacy of Nitroglycerin Inhalation in Reducing Pulmonary Arterial Hypertension in Children with Congenital Heart Disease, 97 British Journal of Anaesthesia, 208-214 (2006). ("Goyal").
- Ex. 1008: Macrae, et al., Inhaled Nitric Oxide Therapy in Neonates and

# DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

#### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.